
**WHAT IS CLAIMED IS:**

1. A crystalline Compound I




(Compound I)

characterized by an XRPD spectrum comprising peaks at 12.6 and 13.5 °2θ ± 0.2º 2θ.

2. The crystalline compound of claim 1, wherein the XRPD spectrum further comprises a peak at 17.3 °2θ ± 0.2º 2θ.

3. A crystalline Compound I



(Compound I)

characterized by a $^{13}$C SSNMR spectrum comprising peaks at 18.6, 164.5, and 171.8 ppm ± 0.2 ppm.

4. The crystalline compound of claim 3, wherein the $^{13}$C SSNMR spectrum further comprises peaks at 21.5, 68.7, 81.7, 102.8, and 151 ppm ± 0.2 ppm.

5. A pharmaceutical composition comprising the crystalline compound of any of claims 1-4 and a pharmaceutically acceptable excipient.

6. A crystalline compound defined in any one of claims of 1-4 or the pharmaceutical composition of claim 5 for the treatment of a human infected with hepatitis C virus.

7. Use of the crystalline compound of any one of claims 1-4 or the pharmaceutical composition of claim 5 for the treatment of a human infected with hepatitis C virus.

8. Use of the crystalline compound of any one of claims 1-4 for the manufacture of a medicament for the treatment of a human infected with hepatitis C virus.